Methods of treating mitochondrial dysfunction

Abstract

This disclosure is directed to methods of treating or preventing mitochondrial dysfunction or mitochondrial disease in a subject comprising administration of probucol, or a pharmaceutically acceptable salt thereof. This disclosure is also directed to methods of diagnosing genetic mitochondrial disease in a subject prior to and in association with said treatment or prevention. This disclosure is also directed to methods of assessing and managing a subject with mitochondrial dysfunction or mitochondrial disease using a composite measurement.

Description

technical field [0001] Disclosed herein are methods of treating or preventing mitochondrial dysfunction or mitochondrial disease in a subject, the methods comprising administering probucol or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of diagnosing an inherited mitochondrial disease in a subject prior to and in connection with said treatment or prophylaxis. Also disclosed herein are methods of managing a patient with mitochondrial dysfunction or mitochondrial disease and assessing the patient's response to a therapeutic intervention by using a composite measurement that combines results from two or more sub-instruments. Also disclosed herein is a method of calculating the composite measurement. Further disclosed herein is an integrated method for diagnosing and treating a human subject with mitochondrial dysfunction or a mitochondrial disease and assessing the patient's response using the composite measurement. Background technique [000...

AI Technical Summary

Problems solved by technology

In this work, probucol was proposed to target only pancreatic beta cells, and thus was not proposed as a multi-organ or broad-spectrum therapeutic agent

Images